1. Introduction {#sec1-proteomes-04-00015}
===============

Musculoskeletal ageing is characterized by age-related muscle fiber atrophy, as a corollary of motor unit (MU) loss \[[@B1-proteomes-04-00015]\]. Each MU comprises a presynaptic motor neuron and a postsynaptic population of mono-innervated skeletal muscle fibers \[[@B2-proteomes-04-00015]\]. MUs are, typically but not always \[[@B3-proteomes-04-00015]\], defined by uniform skeletal muscle fiber isoform (Type I, Type II) content \[[@B4-proteomes-04-00015]\]. Type II MUs are preferentially lost with age, owing to failed re-innervation \[[@B2-proteomes-04-00015]\]. Functionally, type II MU loss underpins age-related phenotypical alterations (e.g., reduced skeletal muscle power \[[@B5-proteomes-04-00015]\]), owing to the distinct contractile and metabolic properties associated with each fiber type (reviewed in \[[@B4-proteomes-04-00015],[@B6-proteomes-04-00015]\]). Therefore, classification of skeletal muscle fiber type can provide insight into the nature of the phenotypical alterations that define musculoskeletal ageing \[[@B7-proteomes-04-00015]\].

Traditional biochemical and histochemical approaches to characterizing skeletal muscle phenotype involve assessment of metabolic enzyme activity (e.g., citrate synthase activity) and myosin heavy chain (MyHC) isoform content and/or ATPase activity \[[@B8-proteomes-04-00015],[@B9-proteomes-04-00015]\]. Such approaches have revealed that musculoskeletal ageing is associated with reduced citric acid cycle and electron transport chain subunit activity and content \[[@B10-proteomes-04-00015],[@B11-proteomes-04-00015]\], although this is modifiable by physical activity levels \[[@B1-proteomes-04-00015]\]. Ageing is also associated with reduced MyHCIIa and MyHCIIx expression, consistent with type II MU loss \[[@B7-proteomes-04-00015]\]. Unfortunately, the techniques used to collect the aforementioned data require relatively large amounts of sample and are ill-suited to multiplex analysis so typically just a few proteins are studied in isolation \[[@B9-proteomes-04-00015],[@B12-proteomes-04-00015],[@B13-proteomes-04-00015],[@B14-proteomes-04-00015]\] and in a serial rather than parallel manner. The latter is a particular concern because metabolic and contractile differences can be uncoupled \[[@B12-proteomes-04-00015],[@B15-proteomes-04-00015]\]. Resultantly, metabolic differences can exist despite similar MyHC isoform content \[[@B12-proteomes-04-00015]\]. The age-related appearance of hybrid skeletal muscle fibers that co-express multiple MyHC isoforms further complicates this issue \[[@B16-proteomes-04-00015]\]. The collective limitations of traditional biochemical and histochemical approaches preclude complete characterization of age and physical activity level phenotypes in skeletal muscle.

Proteomic approaches to characterizing skeletal muscle phenotype confer several important advantages, notably the capacity to analyze multiple proteins in a parallel and un-biased manner \[[@B17-proteomes-04-00015],[@B18-proteomes-04-00015],[@B19-proteomes-04-00015],[@B20-proteomes-04-00015]\]. Consequently, proteomic research has advanced understanding of the phenotypical changes associated with musculoskeletal ageing \[[@B7-proteomes-04-00015],[@B10-proteomes-04-00015],[@B21-proteomes-04-00015],[@B22-proteomes-04-00015],[@B23-proteomes-04-00015],[@B24-proteomes-04-00015],[@B25-proteomes-04-00015]\]. For example, Gelfi *et al.* \[[@B7-proteomes-04-00015]\] reported myosin regulatory light chain (MLRS) content was lower in older compared with younger individuals, which may contribute to age-related contractile dysfunction \[[@B26-proteomes-04-00015]\]. Nevertheless, existing literature is broadly limited by two major caveats. First, the confounding influence of activity levels has seldom been standardized or controlled in human studies. For instance, lower MLRS isoform content of elderly individuals \[[@B7-proteomes-04-00015]\] could reflect reduced physical activity rather than a direct effect of ageing *per se*. Second, inconsistencies exist between proteomic studies in model species (e.g., rodents) compared with humans. For example, in contrast to humans, commonly used rodent models are inbred and rodents express a fast type MyHCII isoform (Type II b \[[@B9-proteomes-04-00015],[@B15-proteomes-04-00015]\]), which is not present in human locomotive muscles.

Two-dimensional gel electrophoresis (2DGE) has been commonly employed in muscle proteomic investigations but this technique has widely acknowledged \[[@B12-proteomes-04-00015],[@B19-proteomes-04-00015],[@B21-proteomes-04-00015],[@B27-proteomes-04-00015],[@B28-proteomes-04-00015],[@B29-proteomes-04-00015]\] technical limitations. In an effort to overcome some of the technical issues associated with 2DGE, we have used a high-performance liquid chromatography coupled mass spectrometry (LC-MS) that affords time-efficient (180 min per sample), automated and quantitative analysis of skeletal muscle samples \[[@B12-proteomes-04-00015]\]. Recent application of this approach identified heart-type fatty acid binding protein as a novel biomarker of aerobic capacity in both rodent and human skeletal muscle samples \[[@B12-proteomes-04-00015]\]; confirming the utility of this novel phenotypical approach. We reasoned that application of LC-MS to the myofibrillar fraction may advance phenotyping by enabling the measurement of isoform expression and splice variation of the myofibrillar proteome. Accordingly, the aims of the present study were to: (1) quantify differences in MyHC content using traditional denaturing gel electrophoresis methods; then (2) mine the myofibrillar proteome using LC-MS/MS; and (3) investigate differences between muscle samples of young and elderly adults using LC-MS label-free profiling. In addition, trained and untrained participants were included in each age group to further dissect the influence of physical activity levels on phenotypical biomarkers of ageing \[[@B10-proteomes-04-00015],[@B11-proteomes-04-00015],[@B30-proteomes-04-00015]\]. Finally, we used multiple reaction monitoring to verify discoveries generated by LC-MS profiling.

2. Results {#sec2-proteomes-04-00015}
==========

2.1. MyHC Isoform Analysis {#sec2dot1-proteomes-04-00015}
--------------------------

Denaturing gel electrophoresis conditions were optimized using a pooled standard (10 µg protein from each individual, *n* = 24). MyHC isoforms (MyHCI, MyHCIIa and MyHCIIx) were successfully resolved into three distinct bands ([Figure 1](#proteomes-04-00015-f001){ref-type="fig"}). MyHC isoform content (MyHCI: 52.4% ± 1.7%, MyHCIIa: 38.4% ± 3.9% and MyHCIIx: 9.2% ± 2.2%) was consistent with previous literature \[[@B31-proteomes-04-00015]\]. Satisfied with the optimization of our electrophoresis protocol, we next analyzed individual samples ([Figure 2](#proteomes-04-00015-f002){ref-type="fig"}). Endurance trained individuals typically exhibit greater Type I fiber content and thus lower Type IIa and Type IIx content compared with untrained individuals, as a function of genetic and environmental factors \[[@B3-proteomes-04-00015],[@B6-proteomes-04-00015],[@B15-proteomes-04-00015]\]. Consistent with this, percentage MyHCI and MyHCIIa levels were greater and lower, respectively, in trained compared with untrained participants ([Table 1](#proteomes-04-00015-t001){ref-type="table"}), irrespective of age \[[@B7-proteomes-04-00015]\]. Type IIa and Type IIx muscle fibers are preferentially lost with age as a consequence of failed re-innervation \[[@B2-proteomes-04-00015]\]. Accordingly, we report MyHCIIa levels were lower in older compared with younger participants, regardless of training status ([Table 1](#proteomes-04-00015-t001){ref-type="table"}). In addition, MyHCIIa and MyHCIIx levels were lower in the old trained (OT) compared with young trained (YT) group. Taken together, our MyHC isoform content analysis confirms known age- and physical activity-related phenotypes.

2.2. LC-MS-MS Mining of the Myofibrillar Proteome {#sec2dot2-proteomes-04-00015}
-------------------------------------------------

Denaturing gel electrophoresis-based MyHC isoform staining approaches are laborious and time consuming, *i.e.*, typically requiring electrophoresis at a stable temperature for \~15 h. Therefore, we investigated whether mass spectrometry-based analyses could provide a more comprehensive and time efficient analysis of muscle phenotype. We first mined the myofibrillar fraction (pooled standard) before quantifying phenotypical differences in individual samples. LC-MS/MS mining of the myofibrillar fraction of a pooled standard identified 47 proteins (M and SD: Mascot Score 5295 ± 8146; Sequence coverage: 34.6% ± 20.4%; Number of peptides: 10 ± 17; [Table 2](#proteomes-04-00015-t002){ref-type="table"}), which represents the most abundant myofibrillar proteins \[[@B28-proteomes-04-00015]\], including the actin-myosin complex, troponins, myosin light chains and tropomyosins ([Figure 3](#proteomes-04-00015-f003){ref-type="fig"}). This demonstrates the potential utility of LC-MS profiling to identify and study multiple isoforms of common myofibrillar proteins in a semi-automated and time-efficient manner.

2.3. Differences in the Myofibrillar Proteome Due to Age or Habitual Levels of Physical Activity {#sec2dot3-proteomes-04-00015}
------------------------------------------------------------------------------------------------

Label-free LC-MS profiling matched 265 peptides across samples from young untrained (YU), young trained (YT), old untrained (OU) and old trained (OT) individuals. Statistical analysis of these data discovered 19 peptides from six proteins exhibited age- and physical activity-related differences ([Table 3](#proteomes-04-00015-t003){ref-type="table"}). Six peptides were specific for different isoforms of myosin essential or regulatory light chains, whereas peptides belonging to MyHC could not be used to unambiguously identify specific isoforms.

Peptide data from label-free profiling were analyzed by two-way analysis of variance. Data represent statistical output (*p* values) of the main comparisons for age (young *versus* old) or training status (trained *versus* untrained) or the interaction between age and training status for each peptide. The retention time and mass-to-charge ratio of each peptide is reported and proteins were identified from the SwissProt database: skeletal muscle actin (ACTS), skeletal muscle myosin regulatory light chain (MLRS), myosin heavy chain (MYH), myosin essential light chain 1 (MYL1), myosin essential light chain 3 (MYL3) and tropomyosin (TPM).

2.4. Confirmation of Age- and Activity-Related Differences in Myosin Light and Regulatory Chain Isoforms Using Selective Reaction Monitoring {#sec2dot4-proteomes-04-00015}
--------------------------------------------------------------------------------------------------------------------------------------------

Label-free LC-MS profiling of the human myofibrillar proteome discovered MLRS, MYL1 and MYL3 abundance may significantly differ as a function of age and physical activity. To verify these discoveries, we further performed selective reaction monitoring of isoform specific tryptic peptides \[[@B12-proteomes-04-00015]\]. The utility of this approach was first confirmed by programming the mass spectrometer to selectively monitor single isoform-specific transitions, for example the doubly charged precursor ion (600.82 *m*/*z*) corresponding to ITLSQVDVLR of human MYL1 and the selective transition to the y6 Fragment ion (658.3 *m*/*z*) illustrated in [Figure 4](#proteomes-04-00015-f004){ref-type="fig"}. Thereafter, we used multiple reaction monitoring (MRM) to quantify ([Table 4](#proteomes-04-00015-t004){ref-type="table"}) the following isoform-specific transitions: 505.7 → 550.2 (MYL1), 600.8 → 658.3 (MYL1), 771.7 → 835.4 (MYL1), 498.2 → 759.4 (MYL3), 600.2 → 735.4 (MLRS) and 762.8 → 780.2 (MLRS).

**MYL1:** MRM analysis of MYL1 revealed that each isoform specific transition was significantly (*p* ≤ 0.05) greater in young compared with old participants, irrespective of training status ([Table 4](#proteomes-04-00015-t004){ref-type="table"}). Accordingly, mean MYL1 isoform abundance was significantly greater (*p* ≤ 0.05) in young compared with old participants. MYL1, is principally expressed in fast twitch fibers \[[@B32-proteomes-04-00015]\] and MYL1 abundance was significantly less in OT (*p* = 0.004) and OU (*p* = 0.045) groups compared with YU group ([Table 5](#proteomes-04-00015-t005){ref-type="table"}). There was also a trend (*p* = 0.63) towards greater MY1 abundance in YU compared with YT. Altogether, MYL1 data are consistent with greater fast twitch fiber abundance in trained compared with untrained participants and an age-related loss of fast twitch muscle fibers in skeletal muscle \[[@B6-proteomes-04-00015],[@B7-proteomes-04-00015],[@B15-proteomes-04-00015],[@B21-proteomes-04-00015]\].

**MYL3:** MYL3, which is enriched in slow skeletal muscle fibers \[[@B13-proteomes-04-00015],[@B33-proteomes-04-00015]\], displayed the reverse profile being significantly (*p* = 0.021) greater in older compared with younger participants, with a trend (*p* = 0.083) towards higher levels in trained compared with untrained participants ([Table 4](#proteomes-04-00015-t004){ref-type="table"}). MYL3 abundance was significantly (*p* = 0.038) less in YU compared with OT. MYL3 abundance was not different (*p* ≥ 0.05) between YT and OT groups ([Table 5](#proteomes-04-00015-t005){ref-type="table"}). MYL3 data are, therefore, consistent with the greater type I fiber content in older compared with younger skeletal muscle \[[@B6-proteomes-04-00015],[@B7-proteomes-04-00015],[@B15-proteomes-04-00015],[@B21-proteomes-04-00015]\], driven by lower levels in YU compared with OT.

**MLRS:** Mean MLRS (also referred to MLC2-f) content was significantly (*p* = 0.031) greater in untrained compared with trained participants, with a trend (*p* = 0.055) towards lower MLRS content in older compared with younger participants ([Table 4](#proteomes-04-00015-t004){ref-type="table"}). Mean MLRS abundance ([Table 5](#proteomes-04-00015-t005){ref-type="table"}) was significantly (*p* = 0.030) greater in YU compared with OT, whereas mean MLRS abundance did not differ (*p* ≥ 0.05) between YU and YT. Therefore, our MLRS data are broadly consistent with greater fast twitch fiber content in untrained compared with trained participants \[[@B6-proteomes-04-00015],[@B7-proteomes-04-00015],[@B15-proteomes-04-00015],[@B21-proteomes-04-00015]\].

Collectively, our data demonstrate that isoform specific myosin light chain transitions are useful phenotypical biomarkers of age and activity related phenomena in human skeletal muscle.

3. Discussion {#sec3-proteomes-04-00015}
=============

We used traditional biochemical analysis of MyHC isoforms to confirm age-related differences in human muscle phenotype and further demonstrate the effect of habitual activity on these data. We expand on our previous work \[[@B12-proteomes-04-00015],[@B28-proteomes-04-00015]\], by using label-free LC-MS profiling to phenotype the human myofibrillar proteome. We resolved 47 myofibrillar proteins without prior orthogonal separation, which is consistent with the well-documented high-abundance of a small number of contractile proteins in skeletal muscle \[[@B17-proteomes-04-00015],[@B19-proteomes-04-00015],[@B20-proteomes-04-00015]\]. Indeed, just ten contractile and metabolic proteins account for over half of the total protein content in skeletal muscle \[[@B29-proteomes-04-00015],[@B30-proteomes-04-00015]\]. LC-MS profiling detected significant differences in the abundance of peptides belonging to essential and regulatory myosin light chains between young and elderly individuals that were either sedentary or undertook regular exercise training. To verify these findings, we performed MRM of selected isoform-specific peptides using a condensed LC gradient with a sample turn-around of 40 min. In addition to verifying novel information regarding age-related differences in myosin light chain abundances, future researchers are able to capitalize on these findings and also perform rapid, semi-automated and parallel profiling of muscle proteins using our reported transitions.

Consistent with previous literature \[[@B7-proteomes-04-00015],[@B21-proteomes-04-00015],[@B31-proteomes-04-00015]\], MyHCIIa abundance, a marker of Type IIa fiber content, was less in older compared with younger individuals, regardless of training status. Indeed, MyHCIIx, a marker of Type IIx content, was almost completely absent in the OT group. MyHCIIa and MyHC IIx phenotypes are likely to be associated with the age-related preferential loss of Type II MU \[[@B2-proteomes-04-00015],[@B34-proteomes-04-00015]\]. The molecular sequelae underpinning Type II MU loss are unclear but this phenomenon may be driven by aberrant repulsive axonal guidance (e.g., Semaphorin 3A) mediated denervation \[[@B34-proteomes-04-00015],[@B35-proteomes-04-00015],[@B36-proteomes-04-00015]\]. Irrespective of age, trained participants displayed greater MyHCI and lesser MyHCIIa abundance compared with untrained participants. This is consistent with greater Type I and lesser Type IIa fiber content in endurance-trained individuals owing to genetic and environmental factors \[[@B6-proteomes-04-00015],[@B15-proteomes-04-00015]\]. Whilst our cross-sectional design precludes causative analysis \[[@B10-proteomes-04-00015]\], MyHC data are consistent with known age- and activity-related phenotypes \[[@B7-proteomes-04-00015],[@B21-proteomes-04-00015],[@B25-proteomes-04-00015]\]. Our ability to confirm existing paradigms of age- and activity-related MyHC phenotypes using traditional analysis meant we could largely exclude the possibility that discoveries made by LC-MS profiling were entirely specific to the population of individuals and instead can be discussed alongside existing literature.

Label-free profiling overcomes many of the technical limitations associated with 1D and 2D gel electrophoresis and could significantly advance phenotyping of skeletal muscle. Nonetheless, LC-MS analysis based solely on intensities of parent ion masses can be confounded by interference from unrelated peptides that share analogous retention times and mass-to-charge ratios \[[@B12-proteomes-04-00015]\]. With this limitation in mind, we sought to verify the age- and activity-related differences in actin, myosin, tropomyosin, MLRS, MYL1 and MYL3 using multiple reaction monitoring (MRM; reviewed in \[[@B37-proteomes-04-00015]\]) This technique selectively monitors and quantifies the intensity of daughter ions from known parent ions (termed transitions \[[@B12-proteomes-04-00015]\]), which greatly enhances the specificity of the analysis. We previously used MRM to confirm that heart-type fatty acid protein was more abundant in rodents artificially selected for higher aerobic capacity compared with lower aerobic capacity \[[@B12-proteomes-04-00015]\], affirming the utility of this approach in skeletal muscle. Application of MRM to the myofibrillar fraction presented a significant analytical challenge owing to high myofibrillar protein sequence homology. For example, MYL1 and MYL3 share 72.6% sequence identify. Consequently, only isoform specific transitions in selected proteins were analyzed.

Myosin essential (MYL1, MYL3) and regulatory (MLRS) light chains were selected for MRM analysis owing to their essential role in regulating contractile velocity \[[@B38-proteomes-04-00015]\] and prior reports of differential expression in old compared with young skeletal muscle \[[@B7-proteomes-04-00015],[@B22-proteomes-04-00015]\]. MYL1 and MLRS are predominately, but not exclusively \[[@B39-proteomes-04-00015],[@B40-proteomes-04-00015]\], expressed in fast twitch muscle, whereas MYL3 is predominately expressed in slow twitch muscle \[[@B13-proteomes-04-00015],[@B24-proteomes-04-00015]\]. Using known age and activity related phenotypes as a conceptual framework \[[@B2-proteomes-04-00015],[@B3-proteomes-04-00015],[@B6-proteomes-04-00015],[@B21-proteomes-04-00015],[@B34-proteomes-04-00015]\], it could be predicted, *a priori*, that: (1) MYL1 and MLRS content should be greater; and (2) MYL3 content should be lesser in the skeletal muscle of elderly compared to young adults. The prediction for MLRS is complicated by conflicting reports of an age-related decrease in MLRS in humans \[[@B7-proteomes-04-00015]\] against a drastic increase in MLRS that demarcates the onset of senescence in rodent skeletal muscle \[[@B26-proteomes-04-00015]\]. Whilst this could be related to interspecies differences \[[@B41-proteomes-04-00015]\], it could equally be attributable to a failure to control for physical activity status particularly in human studies \[[@B1-proteomes-04-00015],[@B42-proteomes-04-00015]\]. We reasoned that the latter was more likely owing to a recent report documenting lower MRLS content in trained compared with recreational runners \[[@B43-proteomes-04-00015]\]. In support of this, we report novel evidence that age-related changes in MLRS abundance could easily be confounded by the physical activity status of the participants. Specifically, MLRS differed as a function of training status and the trend towards differential age-related expression was owing to significantly greater levels in YU compared with OT, but not YT compared with OT. This observation warrants further mechanistic exploration. Future reports may wish to extend our observations by comparing the relative abundance and phosphorylation status of each of the fast and slow regulatory isoforms.

We also report novel data identifying that MYL1 and MYL3 content is lesser and greater, respectively, in the muscle of old compared with younger adults. As a consequence, the ratio between MYL3 and MYL1 is dramatically different between young, elderly, trained and untrained humans ([Table 4](#proteomes-04-00015-t004){ref-type="table"} and [Table 5](#proteomes-04-00015-t005){ref-type="table"}). Our findings are the first of their kind rendering comparison with previous literature difficult. This notwithstanding, MYL1, MYL3 and MLRS data confirm our MyHC analysis and are consistent with the notion that ageing is accompanied by preferential Type II MU loss \[[@B2-proteomes-04-00015],[@B34-proteomes-04-00015]\]. It will, however, be important to confirm this observation with longitudinal studies that permit greater mechanistic insight; as one cannot rule out the possibility that innate fiber type differences between our groups underpinned our observations and not age or physical activity status *per se*. Such caveats should be viewed globally; that is, they are generic to the research field, being unrestricted to the present study owing to the difficulties associated with conducting longitudinal studies of human ageing.

MRM affords semi-automated, rapid and quantitative phenotyping \[[@B12-proteomes-04-00015],[@B37-proteomes-04-00015]\] and the potential wider application of this approach has not escaped our attention. Future investigators may wish to use our data as a resource to perform isoform specific MRM analysis of myosin light chain content; thus, obviating the limitations of traditional methods of muscle phenotyping. In the future, this approach could be further extended by spiking samples with stable isotope-labeled peptides to provide quantitative analysis of human samples.

4. Materials and Methods {#sec4-proteomes-04-00015}
========================

4.1. Participants {#sec4dot1-proteomes-04-00015}
-----------------

Ethical approval was granted from the Liverpool John Moores University Ethics Committee and the present study adhered to the declaration of Helsinki. After providing written informed consent, 12 younger (18--30 years) and 12 older (≥55 years) Caucasian males participated and were segregated according to training history to yield four experimental groups: young trained (YT, *n* = 6), young untrained (YU, *n* = 6), old trained (OT, *n* = 6) and old untrained (OU, *n* = 6). Trained participants were competitive amateur cyclists that had habitually completed at least five endurance sessions per week. Untrained participants did not participate in systematic endurance training and completed ≥3 exercise sessions per week. Basic participant anthropometrical and physiological characteristics have been reported previously \[[@B42-proteomes-04-00015],[@B44-proteomes-04-00015]\].

4.2. Muscle Biopsies {#sec4dot2-proteomes-04-00015}
--------------------

After the administration of a local anesthetic (0.5% Marcaine), muscle biopsies were obtained from the *Vastus Lateralis* using a Bard Monopty disposable biopsy instrument (12 cm × 10 cm gauge, Bard Monopty Systems, Tempe, AZ, USA). Muscle samples were immediately snap frozen in liquid nitrogen and stored at −80 °C until further analysis.

4.3. MyHC Isoform Staining {#sec4dot3-proteomes-04-00015}
--------------------------

Approximately 20--30 mg of frozen muscle tissue was ground to powder and homogenized in 120 μL of ice cold lysis buffer supplemented with phosphatase and protease inhibitors (25 mM Tris/HCl (pH 7.4), 50 mM NaF, 100 mM NaCl, 5 mM EGTA, 1 mM EDTA, 10 mM Na-Pyrophosphatase, 1 mM Na~3~VO~4~, 0.27 M sucrose, 1% Triton X-100, 0.1% 2-mercaptoethanol). Homogenates were centrifuged at 1000 *g* for 10 min at 4 °C. The resultant pellet (myofibrillar protein) was re-suspended in 1% SDS buffer and boiled at 95 °C for 5 min. Protein content was determined using a Bradford assay \[[@B45-proteomes-04-00015]\]. Samples (10 µL equivalent to 0.5 µg·µL^−1^ protein) were separated by molecular weight using an 8% denaturing gel electrophoresis protocol (see \[[@B29-proteomes-04-00015],[@B30-proteomes-04-00015]\]). Samples were electrophoresed on ice for 15 h at 280 V. Polyacrylamide gels were washed (ddH~2~O) and stained with Coomassie blue, as previously described \[[@B46-proteomes-04-00015],[@B47-proteomes-04-00015]\]. Bands were quantified by densitometry analysis on T120 (Total lab., Newcastle upon Tyne, UK) software.

4.4. Label Free Liquid Chromatography Coupled Mass Spectrometry (LC-MS) {#sec4dot4-proteomes-04-00015}
-----------------------------------------------------------------------

The myofibrillar faction was prepared for in-solution digest by precipitating supernatants in 5 volumes of acetone, re-suspending in 0.1% (*w*/*v*) Rapigest SF (Waters; Milford, MA, USA) and 50 mM ammonium bicarbonate before incubation at 80 °C for 15 min. Pellets were reduced with DTT (final concentration 1 mM) at 60 °C for 15 min in the dark before being alkylated with 5 mM at 4 °C for 30 min. Sequence grade trypsin (Promega, Madison, WI, USA) was added at a protein ratio of 1:50 and digestion allowed to proceed at 37 °C overnight. Digestion was terminated by 2 μL concentrated TFA addition. Tryptic peptide solutions were cleared by centrifugation at 13,000 *g* for 15 min at room temperature.

Label free LC-MS analysis was performed on a quadrupole-high capacity ion-trap (HCT Ultra ETD II; Bruker Daltonics, Bremen, Germany) coupled to an online electrospray ionization and nano-flow HPLC system (Ultimate 3000; Dionex, Sunnyvale, CA, USA). Consistent with previous work \[[@B12-proteomes-04-00015]\], tryptic digests (0.8 μg/μL) were diluted 1:10 in 0.1% formic acid (FA) solution. Samples (5 µL) were loaded onto a pre-column (Agilent Technologies Ltd., Santa Carla, CA, USA) and separated on Zorbax 300SB C~18~ 3.5 μm, 15 cm × 75 μm analytical reverse phase column (Agilent Technologies Ltd.) at a flow rate of 300 nL·min^−1^ using a non-linear gradient rising to 40% acetonitrile 0.1% FA over 160 min. Mass spectra for LC-MS profiling were recorded between 200 *m*/*z* and 2500 *m*/*z* using standard enhanced mode (8100 (*m*/*z*)/s). Equivalent data-dependent tandem mass spectrometry (MS/MS) spectra were collected from triplicate analysis of a pooled standard. MS/MS spectra of collision-induced dissociation fragment ions were recorded for the 5 most abundant precursors from each survey scan (350 to 1600 *m*/*z*).

Profile analysis (defined by two attributes: age and physical activity status) was used to calculate peptide regulation ratios. Peptides that significantly differed between group attributes were determined (Profile Analysis Version 4.0; Bruker Daltonics, Bremen, Germany). LC-MS/MS data were combined to identify proteins with a Swiss-Prot database restricted to "Human" on a locally implemented Mascot ([www.matrixscience.com](www.matrixscience.com)) server (version 2.2.03). Peptide/protein identifications were linked to the peptide regulation ratios determined in Profile Analysis and protein regulation ratios were calculated from peptide regulation ratios.

4.5. Selective Reaction Monitoring (SRM) {#sec4dot5-proteomes-04-00015}
----------------------------------------

SRM \[[@B37-proteomes-04-00015]\] was used to verify and quantify differences in myosin light chain 1 (MYL1), myosin light chain 3 (MYL3) and myosin regulatory light chain 2 (MLRS) isoform specific tryptic digests and their associated precursor and product fragment ions. Samples were separated using a linear chromatographic gradient rising to 40% acetonitrile and 0.1% FA over 15 min. Samples were analyzed in duplicate and in a randomized order. Transitions of *m*/*z* 498--759 were monitored for MYL3, *m*/*z* 771--835 and *m*/*z* 600--658 for MYL1, *m*/*z* 660--735 and *m*/*z* 762--780 for MLRS.

4.6. Statistical Analysis {#sec4dot6-proteomes-04-00015}
-------------------------

A two-way ANOVA was employed to determine the influence of age (*i.e.*, young *vs.* old) and physical activity (*i.e.*, trained *vs.* untrained) levels on outcome variables (e.g., MyHC content). To determine where significant differences occurred, significant main effects of age and activity levels were further explored with *post-hoc* Bonferroni tests. An α value of *p* ≤ 0.05 was used for all tests. Statistical analysis was performed on the Statistical Package for Social Sciences (SPSS, version 17.0, SPSS Inc.: Chicago, IL, USA). Data are presented as Mean and SD (±).

5. Conclusions {#sec5-proteomes-04-00015}
==============

We used an advanced analytical workflow to perform phenotypic profiling of the human myofibrillar proteome. In doing so we discovered and verified novel differences in the abundance of essential myosin light chains MYL1 and MYL3 associated with age. Moreover, by studying well-defined populations of physically-active and sedentary individuals we were able to resolve previously conflicting data regarding differences in regulatory myosin light chain content in the muscle of young and elderly adults.
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The following abbreviations are used in this manuscript:

2DGE

Two-dimensional gel electrophoresis

LC-MS

liquid chromatography mass spectrometry

MLRS

Myosin Light Regulatory Chain, fast isoform

MRM

Multiple Reaction Monitoring

MyHC

Myosin Heavy Chain

MYL1

Myosin Light Chain 1

MYL3

Myosin Light Chain 3

MU

Motor unit

OT

Old Trained

OU

Old Untrained

SRM

Selective Reaction Monitoring

YT

Young Trained

YU

Young Untrained

![Separation of MyHC isoforms in human skeletal muscle using denaturing gel electrophoresis: (**A**) representative image of gel lanes showing separation of MyHC isoforms; (**B**) density plot showing area of interest, into distinct bands (IIx, IIa, I) based in differences in migration (pooled standard, *n* = 24); and (**C**) images of lanes aligned with the area of interest.](proteomes-04-00015-g001){#proteomes-04-00015-f001}

![Influence of age and activity levels on MyHC isoform content in human skeletal muscle. Representative image of gel lanes from young trained (**YT**), young untrained (**YU**), old trained (**OT**) and old untrained (**OU**) individuals with clear separation of MyHC isoforms into distinct bands.](proteomes-04-00015-g002){#proteomes-04-00015-f002}

![Illustration of the structure of thin filament (actin) and thick (myosin) filament; and its main protein components that are known to exist as multiple isoforms. Protein identifiers and descriptions are from the SwissProt database. The MOWSE score and sequence coverage for each protein are also reported from the database searches.](proteomes-04-00015-g003){#proteomes-04-00015-f003}

![Selective reaction monitoring of MYL1 transition 600.8 → 658.3. Parent ion MS spectra (**A**) and annotated MS/MS spectra (**B**) of the doubly-charged peptide ITLSQVGDVLR spanning residues 70--80 of MYL1_HUMAN. Selective monitoring (**C**) of the y6 ion (*m/z* 658.3) was used and relative abundance was measured as area under the curve of the extracted ion (*m/z* 600.8 → 658.3) chromatogram (**D**).](proteomes-04-00015-g004){#proteomes-04-00015-f004}
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###### 

Quantitative analysis of MyHC isoform content by group.

  Band      YT            YU            OT               OU            Effect of Age in Trained   Effect of Age in Untrained
  --------- ------------- ------------- ---------------- ------------- -------------------------- ----------------------------
  IIx (%)   9.0 ± 8.3     13.8 ± 13.5   0.2 ± 0.4        9.5 ± 13.1    98% lower                  31% lower
  Iia (%)   35.6 ± 14.2   50.2 ± 15.1   21.7 ± 13.8 \*   30.0 ± 20.7   40% lower                  40% lower
  I (%)     55.4 ± 27.8   36.0 ± 12.1   78.1 ± 14.2 \*   60.5 ± 30.1   41% higher                 68% higher

\* Denotes significant difference (*p* ≤ 0.05) from YU.
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###### 

List of myofibrillar proteins identified by LC-MS-MS in a pooled standard.

  Accession   Protein Name                                          Score    SC (%)   Peptides   MW      pI
  ----------- ----------------------------------------------------- -------- -------- ---------- ------- ------
  MYH3        Myosin-3                                              12,997   20       1          223.8   5.5
  MYH13       Myosin-13                                             5824     14       1          223.5   5.4
  MYH7        Myosin-7                                              31,073   52       71         223.0   5.5
  MYH1        Myosin-1                                              27,777   41       11         223.0   5.5
  MYH2        Myosin-2                                              36,676   51       94         222.9   5.5
  MYH4        Myosin-4                                              18,379   28       1          222.9   5.6
  MYOM2       Myomesin-2                                            116      9        5          164.8   5.8
  MYPC1       Myosin-binding protein C, slow type                   763      17       14         128.2   5.7
  ACTN2       Alpha-actinin-2                                       5705     45       31         103.8   5.2
  LDB3        LIM domain-binding protein 3                          1259     18       9          77.1    9.4
  ALBU        Serum albumin precursor                               1689     41       20         69.3    5.9
  K2C1        Keratin, type II cytoskeletal 1                       171      10       6          66.0    8.8
  PDLI5       PDZ and LIM domain protein 5                          135      15       4          63.9    9.6
  K1C10       Keratin, type I cytoskeletal                          116      6        3          58.8    5.0
  ATPB        ATP synthase subunit beta, mitochondrial              261      21       6          56.5    5.1
  DESM        Desmin                                                1778     39       15         53.5    5.1
  VIME        Vimentin                                              424      14       2          52.6    4.9
  ENOB        Beta-enolase                                          324      47       4          46.9    8.6
  CASQ1       Calsequestrin-1                                       1718     11       2          44.5    3.9
  KCRM        Creatine kinase M-type                                5182     43       1          43.1    6.9
  ACTS        Actin, alpha skeletal muscle                          12,390   63       23         42.0    5.1
  ACTB        Actin, cytoplasmic 1                                  6353     30       1          41.7    5.2
  ALDOA       Fructose-bisphosphate aldolase A                      1159     41.8     9          39.4    9.2
  ALDOC       Fructose-biphosphate aldolase C                       102      18       1          39.4    6.5
  FHL1        Four and a half LIM domains protein 1                 398      14       3          36.2    10.5
  G3P         Glyceraldehyde-3-phosphate dehydrogenase              599      38       7          36.0    9.3
  TNNT1       Troponin T, slow skeletal muscle                      1119     26       6          32.9    5.8
  TPM2        Tropomyosin beta- chain                               7878     38       13         32.8    4.5
  TPM3        Tropomyosin alpha-3 chain                             6338     44       7          32.8    4.5
  TPM1        Tropomyosin alpha- 1 chain                            7298     44       11         32.7    4.5
  TNNT3       Troponin T, fast skeletal muscle                      1262     24       6          31.8    5.6
  MYOZ1       Myozenin-1                                            599      51       7          31.7    9.3
  CAH3        Carbonic anhydrase 3                                  760      38       6          29.5    7.1
  MYL6B       Myosin light chain 6B                                 152      15       1          22.7    5.5
  MYL3        Myosin light chain 3                                  4390     68       10         21.9    4.9
  TNNI1       Troponin I, slow skeletal muscle                      1043     29       5          21.7    10.3
  TNNI2       Troponin I, fast skeletal muscle                      901      14       3          21.3    9.6
  MYL1        Myosin light chain 1/3, skeletal muscle               8270     8        15         21.1    4.8
  MLRS        Myosin regulatory light chain 2, skeletal muscle      7121     72       2          19      4.7
  MLRV        Myosin regulatory light chain 2, venticular/cardiac   3186     72       11         18.8    4.7
  TNNC1       Troponin C, slow skeletal and cardiac                 261      9        2          18.4    3.9
  TNNC2       Troponin C, skeletal muscle                           2162     33       4          18.1    3.9
  MYG         Myoglobin                                             3163     55       8          17.2    7.9
  MYL6        Myosin light polypeptide 6                            1402     30       2          16.9    4.4
  HBB         Hemoglobin subunit beta                               11,403   88       12         16      6.9
  HBD         Hemoglobin subunit delta                              4206     69       2          16      9.1
  HBA         Hemoglobin subunit alpha                              2586     53       6          15.2    9.4
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###### 

Label-free LC-MS-MS profiling of the myofibrillar faction of individual samples.

  Accession                   Retention Time: Mass/Charge Ratio   *p*-Value                                
  --------------------------- ----------------------------------- ----------- ------- -------------------- --------------------
  ACTS                        40.1 min: 644.31 *m*/*z*            0.552       0.289   0.02                 GILTLK
  98.9 min: 895.86 *m/z*      0.024                               0.315       0.336   SYELPDGQVITIGNER     
  44.7 min: 1162.47 *m/z*     0.043                               0.537       0.678   EITALAPSTMK          
  MLRS                        83.4 min: 652.64 *m/z*              0.159       0.029   0.05                 VAPEEHPTLLTEAPLNPK
  103.8 min: 1524.61 *m/z*    0.117                               0.03        0.2     FLEELLTTQCDR         
  32.1 min: 1173.43 *m/z*     0.06                                0.026       0.399   DGIIDKEDLR           
  MYH                         104.4 min: 1319.51 *m/z*            0.045       0.046   0.465                GADPEDVITGAFK
  117.6 min: 895.91 *m/z*     0.026                               0.096       0.211   NAYEESLDQLETLK       
  21.9 min: 1004.37 *m*/*z*   0.268                               0.348       0.041   ELEEISER             
  144.6 min: 1893.88 *m/z*    0.004                               0.051       0.051   LLSTLFANYAGADAPIEK   
  67.1 min: 1507.59 *m/z*     0.015                               0.275       0.302   LTYTQQLEDLKR         
  21.5 min: 1272.36 *m/z*     0.015                               0.51        0.87    TLEDQMNEHR           
  MYL1                        20.0 min: 1411.48 *m/z*             0.876       0.832   0.027                ELTYQTEEDRK
  17.8 min: 1482.51 *m/z*     0.108                               0.555       0.033   KVQHELDEAEER         
  119.4 min: 1010.42 *m/z*    0.508                               0.022       0.444   EAFLLFDR             
  MYL3                        116.4 min: 1542.60 *m/z*            0.001       0.841   0.798                DQATYEDFVEGLR
  22.9 min: 1524.60 *m/z*     0.03                                0.917       0.662   AAPAPAPPPEPERPK      
  TPM                         68.8 min: 1243.50 *m/z*             0.04        0.574   0.63                 IQLVEEELDR
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###### 

Verification of myosin light chain abundances by multiple reaction monitoring.

  Transition             Young         Old           Age (*p* Value)   Trained       Untrained     Activity (*p*-Value)
  ---------------------- ------------- ------------- ----------------- ------------- ------------- ----------------------
  MYL1 (771.7 → 835.4)   1372 ± 669    796 ± 280     0.06              868 ± 388     1343 ± 684    0.024
  MYL1 (600.8 → 658.3)   2790 ± 1309   1682 ± 640    0.007             1761 ± 848    2806 ± 1252   0.013
  MYL1 (505.7 → 550.2)   3829 ± 2133   1764 ± 1187   0.007             2014 ± 1515   3744 ± 2149   0.025
  MYL1 total             2081 ± 977    1239 ± 450    0.006             1315 ± 614    2075 ± 953    0.014
  MLY3 (498.2 → 759.4)   3579 ± 1682   6353 ± 3347   0.021             5881 ± 3140   3867 ± 2403   0.083
  MYL3:MYL1 ratio        1.72          5.13                            4.47          1.86          
  MLRS (660.2 → 735.4)   1029 ± 436    740 ± 399     0.108             701 ± 379     1097 ± 410    0.029
  MLRS (762.8 → 780.2)   2101 ± 1135   1236 ± 834    0.048             1251 ± 904    2164 ± 1080   0.039
  MLRS total             1565 ± 778    988 ± 591     0.055             976 ± 630     1630 ± 725    0.031

Data are presented as mean ± standard deviation (SD) of the area under the curve for each isoform specific transition. Main effect *p* values are presented for statistical analysis by age (young and old) and activity (trained and untrained) level.
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###### 

MRM transition area under the curve by group.

  Isform Specific Transition   YT            YU            OT               OU
  ---------------------------- ------------- ------------- ---------------- ---------------
  MYL1 (771.7 → 835.4)         1034 ± 482    1779 ± 672    703 ± 181 \*     907 ± 356 \*
  MYL1 (600.8 → 658.3)         5777 ± 2532   5707 ± 7583   5457 ± 5430 \*   8436 ± 8908
  MYL1 (505.7 → 550.2)         2829 ± 1822   4829 ± 2072   1199 ± 373 \*    2441 ± 1515
  MYL1 Average                 1568 ± 801    2698 ± 459    1062 ± 186 \*    1451 ± 600 \*
  MYL3 (498.2 → 759.4)         4529 ± 1478   2438 ± 1166   7233 ± 3889 \*   5296 ± 2556
  *MYL3:MYL1 ratio*            *2.89*        *0.90*        *6.81*           *3.65*
  MLRS (762.8 → 780.2)         1632 ± 116    2571 ± 980    869 ± 321 \*     1675 ± 1081
  MLRS (660.2 → 735.4)         829 ± 450     1229 ± 345    573 ± 273 \*     939 ± 46
  MLRS Average                 1231 ± 794    1900 ± 658    721 ± 295 \*     1307 ± 730

Data are presented as mean ± standard deviation (SD) of the area under the curve for each isoform specific transition. \* Denotes significant difference (*p* ≤ 0.05) from YU group.

[^1]: These authors contributed equally to this work.
